Sol Gel Technologies Ltd (NASDAQ:SLGL) has received an average broker rating score of 1.40 (Strong Buy) from the five analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and four have issued a strong buy recommendation on the company. Sol Gel Technologies’ rating score has improved by 6.7% from three months ago as a result of various analysts’ ratings changes.

Brokers have set a 1 year consensus price objective of $19.40 for the company and are forecasting that the company will post ($0.44) EPS for the current quarter, according to Zacks. Zacks has also assigned Sol Gel Technologies an industry rank of 188 out of 255 based on the ratings given to its competitors.

Several analysts have issued reports on SLGL shares. Zacks Investment Research downgraded shares of Sol Gel Technologies from a “hold” rating to a “sell” rating in a report on Saturday, May 19th. HC Wainwright started coverage on shares of Sol Gel Technologies in a report on Monday, July 16th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, ValuEngine raised shares of Sol Gel Technologies from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of Sol Gel Technologies traded up $0.13, hitting $6.98, on Monday, according to Marketbeat.com. The company’s stock had a trading volume of 4,141 shares, compared to its average volume of 19,834. Sol Gel Technologies has a 12-month low of $6.18 and a 12-month high of $16.48. The company has a market capitalization of $129.62 million and a PE ratio of -1.39.

Sol Gel Technologies (NASDAQ:SLGL) last announced its quarterly earnings results on Tuesday, May 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.06). The business had revenue of $0.04 million for the quarter. equities research analysts expect that Sol Gel Technologies will post -2.05 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. purchased a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $103,000. DAFNA Capital Management LLC purchased a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $361,000. Guggenheim Capital LLC purchased a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $1,073,000. Nexthera Capital LP purchased a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $5,334,000. Finally, Delek Group Ltd. purchased a new position in shares of Sol Gel Technologies during the first quarter valued at approximately $10,703,000. 22.29% of the stock is currently owned by institutional investors and hedge funds.

About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Sol Gel Technologies (SLGL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.